DT Cloud Star Acquisition Corporation trades three related tickers on Nasdaq, with DTSQR representing the rights that detach from the units and settle into one-ninth of an ordinary share upon a consummated business combination. The rights are a derivative play on DT Cloud Star, a special purpose acquisition company that completed a $69,000,000 initial public offering on July 26, 2024, raised an additional $2,069,000 in a private placement with the sponsor, and is now within months of a definitive agreement with PrimeGen US, Inc. at an implied equity value of approximately $1.5 billion. The rights themselves carry no economic claim on the trust and no redemption floor, so the DTSQR market price is a function of three forces: the probability that DT Cloud Star's proposed merger closes, the pace of any further public-share redemptions, and the time value embedded in the warrant-style 1/9 conversion ratio.
The investment case rests on three variables. The first is the closing probability of the PrimeGen US business combination announced February 4, 2026, with the parties guiding to a second-half 2026 close and PrimeGen having completed a Pre-Investigational New Drug meeting with the FDA for an Acute Alcoholic Hepatitis program on December 17, 2025. The second is the post-redemption trust balance, which already shrank from approximately $69,000,000 in gross IPO proceeds to $18,421,078 as of June 30, 2026 after 5,247,491 public shares were tendered at a vote, leaving just 1,652,509 public shares outstanding at a redemption value of $11.15 per share. The third is the relative discount or premium of DTSQR to its one-ninth settlement value plus optionality value, because as redemptions and share-count erosion compress the public float, the rights' leverage on the residual trust and on any positive surprise from the merger re-prices.
The thesis confirms if the PrimeGen transaction closes on the disclosed terms, the redomestication merger mechanics settle, and the surviving public company lists under a new ticker with PrimeGen's stem cell and exosome programs intact. The thesis breaks if the trust runs out before close, if minimum cash conditions in the business combination agreement are not satisfied, if shareholders of either company vote down the merger, or if the redemption activity erodes the float to a level where Nasdaq listing compliance is no longer a given. The most recent 10-Q, for the period ended June 30, 2026, raises substantial doubt about the company's ability to continue as a going concern absent a successful business combination, and the rights sit downstream of every operational decision made at the parent SPAC level.